{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double-Expressor+Lymphoma",
    "query": {
      "condition": "Double-Expressor Lymphoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T15:07:45.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06736613",
      "title": "A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Stage III High Grade B-Cell Lymphoma",
        "Stage IV High Grade B-Cell Lymphoma",
        "DLBCL - Diffuse Large B Cell Lymphoma",
        "Intravascular Large B-Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma of Breast",
        "Diffuse Large B Cell Lymphoma of Testis",
        "HIV-associated Diffuse Large B Cell Lymphoma",
        "Double Expressor DLBCL"
      ],
      "interventions": [
        {
          "name": "Cerebral Spinal Fluid ctDNA",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-12-11",
      "completion_date": "2027-12-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06736613"
    },
    {
      "nct_id": "NCT04479267",
      "title": "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements",
        "Double Expressor Lymphoma",
        "High-grade B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2020-08-21",
      "completion_date": "2026-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-09-29",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04479267"
    },
    {
      "nct_id": "NCT05600686",
      "title": "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Loncastuximab Tesirine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Joseph Tuscano",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-24",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Diego, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05600686"
    },
    {
      "nct_id": "NCT03984448",
      "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma",
        "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Double-Expressor Lymphoma",
        "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present",
        "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 363,
      "start_date": "2019-10-22",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 635,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 434 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984448"
    },
    {
      "nct_id": "NCT07069699",
      "title": "Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Burkitt Lymphoma",
        "Double-Expressor Lymphoma",
        "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Pidnarulex",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-10-13",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 4,
      "location_summary": "Irvine, California • Orange, California • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07069699"
    },
    {
      "nct_id": "NCT01742988",
      "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Relapsed Lymphoma",
        "Refractory Lymphoma",
        "Relapsed and/or Refractory Lymphoma",
        "Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)",
        "Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Double-hit Lymphoma (DHL)",
        "Triple-hit Lymphoma (THL)",
        "Double-expressor Lymphoma (DEL)",
        "High-grade B-cell Lymphoma (HGBL)"
      ],
      "interventions": [
        {
          "name": "fimepinostat",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Curis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2012-12",
      "completion_date": "2020-10-09",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-06-25T15:07:45.357Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01742988"
    }
  ]
}